Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3130-3135

  Nicoll, A J ^a   Colledge, D L ^a   Toole, J J ^b   Angus, P W ^c   Smallwood, R A ^c   Locarnini, S A ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b GILEAD SCIENCES   (United States)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; GANCICLOVIR; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA; VIRUS PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DUCK; EXPERIMENTAL INFECTION; HEPATITIS B; HEPATITIS B VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER FUNCTION TEST; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0031728650     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3130     Document Type: Article

References (41)

1. Aye, T., A. Bartholomeusz, T. Shaw, D. Bowden, A. Breschkin, J. McMillan, P. Angus and S. Locarnini. 1997. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1148-1153.
2. Beasley, R. P., L. Y. Hwang, C. C. Lin, and C. S. Chien. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet ii:1129-1133.
3. Bishop, N., G. Civitico, Y. Y. Wang, K. Guo, C. Birch, I. Gust, and S. A. Locarnini. 1990. Antiviral strategies in chronic hepatitis B virus infection. I. Establishment of an in vitro system using the duck hepatitis B virus model. J. Med. Virol. 3:82-89.
4. Blum, H. E., L. Stowring, A. Figus, C. Montgomery. A. Haase, and G. Vyas. 1983. Detection of hepatitis B virus DNA in hepatocytes,. bile duct epithelium, and vascular elements by in situ hybridization. Proc. Natl. Acad. Sc., USA 80:6685-6688.
5. Boker, K. H. W., B. Ringe, M. Kruger, R. Pichlmayr, and M. P. Manns. 1994. Prostaglandin E plus famciclovir - a new concept for the treatment ot severe hepatitis B after liver transplantation. Transplantation 57:1706-1708.
6. Calio, R., N. Villani, E. Balestra, F. Sesa, A. Holy, J. Balzarini, E. De Clercq, C. F. Perno, and V. Del Gobbo. 1994. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antivir. Res. 23:77-89.
7. Collier, A., R. Coombs, J. Nienow, M. Paradise, H. Yang, S. Troxel, J. Boggs, D. Ebeling, H. Jaffe, and L. Corey. 1994. A phase I/II study of 9-(2-phosphoylmethoxyethy)adenine (PMEA) in advanced HIV infection. In Proceeding of the First International Conference on Human Retroviruses.
8. Dean, J., S. Bowden, and S. Locarnini. 1995. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antivir. Res. 27:171-178.
9. De Clercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
10. Del Gobbo, V., A. Foli, J. Balzarini, E. De Clerq, E. Balestra, N. Villani, S. Marini, C. Perno, and R. Calio. 1991. Immunomodulatory activity of 9-(2-phosphonylmethoxyethy)adenine (PMEA), a potent anti-HIV nucleoside analogue on in vivo murine models. Antivir. Res. 16:65-75.
11. Delladetsima, J. K., I. Vafiadis, N. C. Tassopoulos, V. Kyriakou, A. Apostolaki, and T. Smyrnoff. 1994. HBcAg and HBsAg expression in ductular cells in chronic hepatitis B. Liver 14:71-75.
12. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
13. Gilson, R., K. Chopra, I. Murray-Lyon, A. Newell, M. Nelson, R. Tedder, J. Toole, H. Jaffe, N. Hellmann, and I. Weller. 1996. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. Hepatology 24:281A. (Abstract.)
14. Heijtink, R. A., G. A. De Wilde, J. Kruining, L. Berk, J. Balzarin,. E. De Clercq, A. Holy, and S. W. Schalm. 1993. Inhibitory effect ot 9-2-phosphonylmethoxyethyladenine (PMEA) on human and duck hepatitis B virus infection. Antivir. Res. 21:141-153.
15. Heijtink, R. A., J. Kruining, G. A. De Wilde, J. Balzarini, E. De Clercq, and S. W. Schalm. 1994. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
16. Jilbert, A. R., J. S. Freiman, C. J. Burrell, M. Holmes, E. J. Gowans, R. Rowland, P. Hall, and Y. E. Cossart. 1988. Virus-liver cell interactions in duck hepatitis B virus infection. A study of virus dissemination within the liver. Gastroenterology 95:1375-1382.
17. Kane, M. 1996. Global status of hepatitis B immunization. Lancet 348:696.
18. Kejian, G., and D. S. Bowden. 1991. Digoxigenin-labeled probes for the detection of hepatitis B virus DNA in serum. J. Clin. Microbiol. 29:506-509.
19. Kruger, M., H. L. Tillmann, C. Trautwein, V. Bode, K. Oldhafer, K. H. Boker, R. Pichlmayr, and M. Manns. 1994. Treatment of hepatitis B virus re-infection after liver transplantation with famciclovir. Hepatology 20:130A.
20. Lai, C. L., C. K. Ching, A. Tung, A. M. Hill, B. C. Y. Wong, S.P. Lim, J. C. Dent, and P. C. Wu. 1994. Short term lamivudine suppresses HBV DNA in Chinese HBsAg carriers. Hepatology 20:298A.
21. Lin, E., C. Luscombe, Y. Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 40:413-418.
22. Luscombe, C., J. Pedersen, E. Uren, and S. Locarnini. 1996. Longterm ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic viral DNA, RNA and protein expression. Hepatology 24:766-773.
23. Luscombe, C. A., J. Pederson, S. Bowden, and S. Locarnini. 1994. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 14:182-102.
24. Main J., J. Brown, C. Howells, R. Galassini, M. Crossey, P. Karayiannis, P. Georgiou, G. Atkinson, and H. Thomas. 1996. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 3:211-215.
25. Main, J., L. Brown, P. Karayiannis, P. Georgiou, M. Boyd, W. Prince, and H. Thomas. 1994. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Hepatol. 21(Suppl. 1):S32.
26. Marinos, G., H. M. Smith, N. V. Naoumov, and R. Williams. 1994. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection. Hepatology 19: 303-311.
27. Milich, D. R., J. E. Jones, J. L. Hughes, J. Price, A. K. Raney, and A. McLachlan. 1990. Is a function of the secreted hepatitis B e antigen to induce immunological tolerance in utero? Proc. Natl. Acad. Sci. USA 87: 6599-6603.
28. Naesens, L., J. Neyts, J. Balzarini, A. Holy, I. Rosenberg, and E. De Clerq. 1993. Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. J. Med. Virol. 39:167-173.
29. Nicoll, A., P. Angus, S. Chou, C. Luscombe, R. Smallwood, and S. Locarnini, 1997. Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection. Hepatology 25:463-469.
30. Nicoll, A., S. Locarnini, S. Chou, R. Smallwood, and P. Angus. 1996. Human hepatitis B virus infection of bile duct epithelial cells. Hepatology 24(4 Pt. 2):221A.
31. Niu, J., Y. Wang, R. Dixon, S. Bowden, M. Qiao, L. Einck, and S. Locarnini. 1993. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antivir. Res. 21:155-171.
32. Omata, M. K. Hirota, and O. Yokosuka. 1986. In vivo study of the mechanism of action of antiviral agents against hepadnavirus replication in the liver. J. Hepatol. 3(Suppl. 2):S40-S55.
33. Shaw, T., and S. Locarnini. 1995. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 15:169-184.
34. Sherker, A., and P. Marion. 1991. Hepadnaviruses and hepatocellular carcinoma. Annu. Rev. Microbiol. 45:475-508.
35. Srinivas, R. V., B. L. Robbins, M. C. Connelly, Y. F. Gong, N. Bischofberger, and A. Fridland. 1903. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 37:2247-2250.
36. Starrett, J. E., D. R. Tortolani, M. J. M. Hitchcock, J. C. Martin, and M. M. Mansuri. 1992. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl)9-(2-phosphonylmethoxyethyl)adenine. Antivir. Res. 19:267-273.
37. Tyrrell, D. L. J., M. C. Mitchell, R. A. De Man, S. W. Schalm, J. Main, H. C. Thomas, J. Fever, F. Nevens, P. Beranek, and C. Vicary. 1993. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18:112A.
38. Walker, R., S. Vogel, H. Jaffe, M. Polis, J. Kovacs, J. Falloon, R. Davey, D. Ebeling, K. Cundy, D. Paar, M. Markowitz, H. Masur, and H. Lane. (1944). A phase I/II study of PMEA in HIV infected patients. In Proceedings of the First International Conference on Human Retroviruses.
39. Wang, Y., S. Bowden, T. Shaw, G. Civitico, Y. Chan, M. Qiao, and S. Locarnini. 1991. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine). Antivir. Chem Chemother. 2:107-114.
40. Wang, Y., C. Luscombe, S. Bowden, T. Shaw, and S. Locarnini. 1995. Inhibition of duck hepatitis B virus DNA replication by antiviral therapy with ganciclovir-nalidixic acid. Antimicrob. Agents Chemother. 39:556-558.
41. Xiong, X., C. Flores, C. Gibbs, and J. Toole. 1997. Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express lamivudine resistance codons. Hepatology 26:431A.